T1	Participants 82 110	metastatic colorectal cancer
T2	Participants 282 494	patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
T3	Participants 817 859	patients with metastatic colorectal cancer
T4	Participants 993 1023	Patients receiving panitumumab
T5	Participants 1454 1482	panitumumab-treated patients
